scholarly journals A Rare Case of Extracavitary Primary Effusion Lymphoma in the Bladder and Ureter

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Jiankun Tong ◽  
Sana Jadallah ◽  
William H. Rodgers ◽  
Gabriel Jung ◽  
Malvina Fulman ◽  
...  

Primary effusion lymphoma (PEL) is a rare and very aggressive large B-cell lymphoma usually presenting as serous effusions without a tumor mass. It is universally associated with human herpesvirus type-8 (HHV-8) infection. It most commonly occurs in the body cavities and rarely develops as solid tumor masses in the wall of cavity and other organs, and it has been termed as extracavitary PEL. Extracavitary PEL has been reported in the lymph nodes and extranodal sites. Here we report a rare case of extracavitary PEL occurring in the bladder and ureter of a human immunodeficiency virus (HIV)-negative 76-year-old Chinese male, presenting with right leg swelling, erythema, and pain. To the best of our knowledge, this is the first case of extracavitary PEL presenting in the bladder and ureter.

2021 ◽  
Author(s):  
Elias Fiani ◽  
Rafca Challita ◽  
Hanaa Badawaki ◽  
Khaled Soukarieh ◽  
Melissa Kyriakos Saad ◽  
...  

Epstein–Barr virus (EBV) is a common herpes virus (human herpesvirus type 4) that usually manifests as infectious mononucleosis or persists asymptomatically for life. EBV can also be associated with different types of malignancy such as T cell lymphoma, B cell lymphoma, Hodgkin lymphoma, and oropharyngeal squamous cell and nasopharyngeal carcinoma. Pneumonia is a very rare complication of EBV infection, but it has been reported to occur even in the absence of mononucleosis. This article highlights the case of 35-year-old female who developed acute pancreatitis and acute respiratory failure related to EBV infection. The patient progressively recovered on antiviral therapy and steroids.


Blood ◽  
2020 ◽  
Vol 136 (11) ◽  
pp. 1284-1297 ◽  
Author(s):  
Juan C. Ramos ◽  
Joseph A. Sparano ◽  
Amy Chadburn ◽  
Erin G. Reid ◽  
Richard F. Ambinder ◽  
...  

Abstract EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus type-8 (HHV-8) positive. The histone deacetylase (HDAC) inhibitor vorinostat disrupts EBV/HHV-8 latency, enhances chemotherapy-induced cell death, and may clear HIV reservoirs. We performed a randomized phase 2 study in 90 patients (45 per study arm) with aggressive HIV-NHLs, using dose-adjusted EPOCH (plus rituximab if CD20+), alone or with 300 mg vorinostat, administered on days 1 to 5 of each cycle. Up to 1 prior cycle of systemic chemotherapy was allowed. The primary end point was complete response (CR). In 86 evaluable patients with diffuse large B-cell lymphoma (DLBCL; n = 61), plasmablastic lymphoma (n = 15), primary effusion lymphoma (n = 7), unclassifiable B-cell NHL (n = 2), and Burkitt lymphoma (n = 1), CR rates were 74% vs 68% for EPOCH vs EPOCH-vorinostat (P = .72). Patients with a CD4+ count <200 cells/mm3 had a lower CR rate. EPOCH-vorinostat did not eliminate HIV reservoirs, resulted in more frequent grade 4 neutropenia and thrombocytopenia, and did not affect survival. Overall, patients with Myc+ DLBCL had a significantly lower EFS. A low diagnosis-to-treatment interval (DTI) was also associated with inferior outcomes, whereas preprotocol therapy had no negative impact. In summary, EPOCH had broad efficacy against highly aggressive HIV-NHLs, whereas vorinostat had no benefit; patients with Myc-driven DLBCL, low CD4, and low DTI had less favorable outcomes. Permitting preprotocol therapy facilitated accruals without compromising outcomes. This trial was registered at www.clinicaltrials.gov as #NCT0119384.


AIDS Care ◽  
2017 ◽  
Vol 30 (3) ◽  
pp. 378-382 ◽  
Author(s):  
Lyana Rodrigues Pinto Lima ◽  
Luis Eduardo Barros Costa Fernandes ◽  
Daniel A. M. Villela ◽  
Mariza Gonçalves Morgado ◽  
José Henrique Pilotto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document